PD‐L1 expression in patients with non‐small‐cell lung cancer is associated with sex and genetic alterations: A retrospective study within the Caucasian population

Abstract

Abstract Background Programmed cell death‐ligand 1 (PD‐L1) expression is a well‐established biomarker for predicting responses to immune checkpoint inhibitors and certain targeted therapies. As a result, treatment strategies for patients vary based on their PD‐L1 expression status. Understanding the clinical features of patients with distinct PD‐L1 levels is crucial for personalized treatment approaches. Methods Demographic and clinicopathological characteristics of 227 patients (54% male, mean age 67 ± 9.9 years) newly diagnosed with non‐small‐cell lung cancer (NSCLC) between April 2020 and December 2022 were retrospectively compared among three groups based on the PD‐L1 expression: PD‐L1 Tumor Proportion Score (TPS) negative, 1–50%, and ≥50%. Logistic regression analysis was performed to evaluate predictors for high PD‐L1 expression ≥50%. Results PD‐L1 expression levels were distributed as follows: negative in 29% of patients, between 1% and 50% in 41%, and greater than 50% (high) in 29%. In comparison to negative PD‐L1 expression, low and high PD‐L1 expression was associated with female sex (32.9% vs. 52.7% vs. 50.7%, p = 0.031), with the absence of epidermal growth factor receptor (EGFR) mutations (83.6% vs. 91.1% vs. 98.1% p = 0.029), and with the absence of ERBB2 (HER2) tyrosine kinase mutations (90.9% vs. 100% vs. 98.1% p = 0.007), respectively. Age, smoking status, histological subtype, and disease stage showed no significant differences among the three patient groups. In the univariate logistic regression, EGFR mutation appeared to be the only predictor for PD‐L1 expression, although it did not reach statistical significance (p = 0.06). Conclusion Although sex and genomic alterations are associated with PD‐L1 expression in patients with NSCLC, no clinical characteristics seem to predict PD‐L1 expression significantly.

Keywords

• gender medicine
• genetic aberrations
• non‐small cell lung cancer
• PD‐L1 status